Tiezzi, D.G.; Buzatto, I.P.C.; Silveira, W.A.d.; Monti, A.C.; Buono, F.d.O.; Meola, J.; Poli-Neto, O.B.; Pagnotta, S.M.
The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy. Int. J. Mol. Sci. 2025, 26, 11809.
https://doi.org/10.3390/ijms262411809
AMA Style
Tiezzi DG, Buzatto IPC, Silveira WAd, Monti AC, Buono FdO, Meola J, Poli-Neto OB, Pagnotta SM.
The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy. International Journal of Molecular Sciences. 2025; 26(24):11809.
https://doi.org/10.3390/ijms262411809
Chicago/Turabian Style
Tiezzi, Daniel Guimarães, Isabela Panzeri Carlotti Buzatto, Willian Abraham da Silveira, Anna Clara Monti, Fabiana de Oliveira Buono, Juliana Meola, Omero Benedicto Poli-Neto, and Stefano Maria Pagnotta.
2025. "The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy" International Journal of Molecular Sciences 26, no. 24: 11809.
https://doi.org/10.3390/ijms262411809
APA Style
Tiezzi, D. G., Buzatto, I. P. C., Silveira, W. A. d., Monti, A. C., Buono, F. d. O., Meola, J., Poli-Neto, O. B., & Pagnotta, S. M.
(2025). The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy. International Journal of Molecular Sciences, 26(24), 11809.
https://doi.org/10.3390/ijms262411809
